Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule for nasal irrigation or nebulizer use containing levofloxacin hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing levofloxacin are listed in tablet, injection and solution forms. No finished levofloxacin product of any kind is listed in capsule form. None of the FDA-approved levofloxacin products is for nasal use.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Levofloxacin is a fluoroquinolone antibiotic that a pharmacy may compound into other dosage forms when a prescriber orders it.
Levofloxacin is a fluoroquinolone antibiotic, the active L-isomer of ofloxacin. It kills bacteria by blocking DNA gyrase and topoisomerase IV, enzymes bacteria need to copy and repair their DNA. The original brand, Levaquin, is no longer marketed; generic tablets, oral solution, intravenous injection and ophthalmic drops are manufactured. Levofloxacin tablet labels list treatment of pneumonia, skin infections, chronic bacterial prostatitis, urinary tract and kidney infections, flares of chronic bronchitis and sinusitis, plus post-exposure inhalational anthrax and plague, in adults and in children where indicated. Because of serious risks, the label reserves it for uncomplicated urinary tract infection, bronchitis flares and sinusitis only when no other options exist. A prescriber might order it compounded in a strength or form that is not manufactured, or without a specific excipient. Compounded preparations are not FDA-approved and require a prescription.
Levofloxacin carries a boxed warning: fluoroquinolones have been linked to disabling and potentially irreversible serious reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy and central nervous system effects, and they can worsen muscle weakness in myasthenia gravis. Other label warnings include serious allergic reactions, liver injury, aortic aneurysm and dissection, C. difficile diarrhea, QT prolongation, low or high blood sugar, and sun sensitivity. Tendon risk is higher after age 60, with corticosteroids, and after organ transplant. Do not take it if you are allergic to any quinolone. Separate antacids, iron, zinc, sucralfate and multivitamins by at least two hours; warfarin and diabetes medicines need closer monitoring. No drug-associated birth defect risk was found; the label and LactMed differ on breastfeeding. Stop it and contact your prescriber or pharmacist right away for tendon pain, numbness or tingling, or mood or behavior changes.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV. Oral absolute bioavailability is approximately 99 percent with peaks at one to two hours, serum protein binding is about 24 to 38 percent, and it is excreted largely unchanged in urine with a terminal half-life of about 6 to 8 hours, prolonged in renal impairment. Labeled indications for levofloxacin tablets (Lupin) include nosocomial and community-acquired pneumonia, skin and skin structure infections, chronic bacterial prostatitis, post-exposure inhalational anthrax, plague, complicated and uncomplicated urinary tract infection, acute pyelonephritis, acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis; StatPearls notes an ophthalmic formulation for bacterial conjunctivitis. StatPearls lists diabetic foot infection and osteomyelitis as off-label uses; these are not FDA-approved indications. Avoid in myasthenia gravis, known QT prolongation or uncorrected hypokalemia, use caution in older adults on corticosteroids, and adjust for renal function. Monitor glucose in diabetes and INR with warfarin. The label suggests pumping and discarding milk, or not breastfeeding, during treatment and for two days after, while LactMed considers it acceptable with infant monitoring. Dosing is per prescriber. Levofloxacin is not a controlled substance.
Wash your hands. Open one capsule and empty the powder into the volume of saline or water on your label, using only distilled, sterile, or boiled and cooled water if you are mixing it yourself. Stir or shake until dissolved. For a sinus rinse, lean over a sink and rinse each nostril with the device. For a nebulizer, pour the solution into the medicine cup and breathe normally through the mouthpiece or mask until the mist stops. Wash and air dry the rinse device or nebulizer cup after each use. Discard any mixed solution you do not use.
Keep the unopened capsules tightly closed in a dry place at room temperature and out of reach of children. The beyond-use date on your label depends on how the capsules were prepared and what they are for; the pharmacist sets it. Mix only one dose at a time and discard capsules after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Empty contents of 1 capsule and mix with saline solution and irrigate/nebulize
